Lantern Pharma Inc. — SEC Form D Filing

Lantern Pharma Inc. filed an SEC Form D on May 21, 2026 in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
May 21, 2026
Industry
Pharmaceuticals
Website
https://www.lanternpharma.com/

What the company does

Securities: Equity, private placement of common stock purchase warrants;claiming additional Section 4(a)(2) exemption. Exemption: Rule 506(b). Incorporated: TEXAS

Problem

The current oncology drug development process is time-consuming, costly, and carries a high risk of failure, with only a 6% success rate for cancer drugs in clinical trials.

Solution

Lantern Pharma is leveraging A.I., machine learning, and genomics to speed up oncology drug discovery and development. The company is advancing drug candidates like LP-184 and LP-284 targeting DNA repair deficient cancers, as well as conducting the Harmonicâ„¢ Clinical Trial for LP-300 in non-small cell lung cancer.

Why now

The need for innovative solutions in oncology drug development is urgent due to the high mortality rates associated with cancer and the inefficiencies in current drug development processes.

Verdict

Investors said yes because they saw an opportunity in leveraging AI to transform a notoriously inefficient oncology drug development process, not because of any unique drug candidates alone. Implicitly, they were betting on the scalability of AI-driven methodologies to generate faster, more effective drug discovery outcomes. However, the narrative's limited upside lies in its dependency on established pharmaceutical markets that are slow to change, restricting the potential for a substantial competitive edge.

Source: SEC EDGAR Form D filing